[1]陈茉 徐书杭 刘超.甲状腺微小癌的热消融治疗[J].国际内分泌代谢杂志,2019,39(06):405-408,418.[doi:10.3760/cma.j.issn.1673-4157.2019.06.011]
　Chen Mo,Xu Shuhang,Liu Chao.Thermal ablation of thyroid microcarcinoma[J].International Journal of Endocrinology and Metabolism,2019,39(06):405-408,418.[doi:10.3760/cma.j.issn.1673-4157.2019.06.011]
点击复制

甲状腺微小癌的热消融治疗()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年06期
页码:
405-408,418
栏目:
综述
出版日期:
2019-11-20

文章信息/Info

Title:
Thermal ablation of thyroid microcarcinoma
作者:
陈茉 徐书杭 刘超
南京中医药大学附属中西医结合医院(江苏省中医药研究院)内分泌科 210028
Author(s):
Chen Mo;  Xu Shuhang;  Liu Chao
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China
关键词:
甲状腺微小癌;  甲状腺微小乳头状癌;  热消融
Keywords:
Thyroid microcarcinoma;  Thyroid papillary microcarcinoma;  Thermal ablation
DOI:
10.3760/cma.j.issn.1673-4157.2019.06.011
摘要:
甲状腺微小癌包括各种亚型的甲状腺癌,但主要指甲状腺微小乳头状癌(PTMC),其发病率增长迅速但复发率和死亡率均无明显增加。热消融作为近年来发展迅速的新技术,包括激光消融、射频消融及微波消融。国内已有多个研究者尝试将其用于PTMC的一线治疗,具有一定的有效性和安全性。虽然目前已有一些指南和共识提出了热消融的指征,但最佳的适应证、术前评估肿瘤和淋巴结情况、合理的术后管理等,仍是热消融用于PTMC一线治疗需要面临的巨大挑战。
Abstract:
Thyroid microcarcinoma, including various subtypes of thyroid cancer, mainly refers to thyroid papillary microcarcinoma(PTMC). The incidence of PTMC has raised rapidly, but the recurrence and the mortality had no significant increase. As a new technique developed rapidly in recent years, thermal ablation, including laser ablation, radiofrequency ablation and microwave ablation, has been attempted as the first-line treatment of PTMC due to its good efficacy and safety. Although some indications of thermal ablation have suggested by a few of guidelines and consensus, appropriate indications, preoperative evaluation of tumor and lymph glands and suitable postoperative management have still been challenging for thermal ablation used in the first-line treatment of PTMC.

参考文献/References:

[1] Handra-Luca A.Thyroid follicular microcarcinoma[J].Int J Surg Pathol,2018,26(3):236-237.DOI:10.1177/1066896917733102.
[2] Kim JH,Pyo JS,Cho WJ.Clinicopathological significance and prognosis of medullary thyroid microcarcinoma: a meta-analysis[J].World J Surg,2017,41(10):2551-2558.DOI:10.1007/s00268-017-4031-6.
[3] Lim H,Devesa SS,Sosa JA,et al.Trends in thyroid cancer incidence and mortality in the united states, 1974-2013[J].JAMA,2017,317(13):1338-1348.DOI:10.1001/jama.2017.2719.
[4] Leboulleux S,Tuttle RM,Pacini F,et al.Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?[J].Lancet Diabetes Endocrinol,2016,4(11):933-942.DOI:10.1016/S2213-8587(16)30180-2.
[5] Haugen BR,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid,2016,26(1):1-133.DOI:10.1089/thy.2015.0020.
[6] Kim JH,Baek JH,Lim HK,et al.2017 Thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology[J].Korean J Radiol,2018,19(4):632-655.DOI:10.3348/kjr.2018.19.4.632.
[7] 中国医师协会甲状腺肿瘤消融治疗技术专家组,中国抗癌协会甲状腺癌专业委员会,中国医师协会介入医师分会超声介入专业委员会,等.甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗专家共识(2018版)[J].中国肿瘤,2018,27(10):768-773.
[8] 陈茉,徐书杭,许洋,等.经皮微波消融治疗良性无功能甲状腺结节疗效和超声形态分析[J]. 国际内分泌代谢杂志,2019,39(5):294-297,301.DOI: 10.3760/cma.j.issn.1673-4157.2019.05.002.
[9] Papini E,Guglielmi R,Gharib H,et al.Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: a potential therapeutic approach in patients at surgical risk[J].Thyroid,2011,21(8):917-920.DOI:10.1089/thy.2010.0447.
[10] Valcavi R,Piana S,Bortolan GS,et al.Ultrasound-guided percutaneous laser ablation of papillary thyroid microcarcinoma: a feasibility study on three cases with pathological and immunohistochemical evaluation[J].Thyroid,2013,23(12):1578-1582.DOI:10.1089/thy.2013.0279.
[11] Zhou W,Jiang S,Zhan W,et al.Ultrasound-guided percutaneous laser ablation of unifocal T1N0M0 papillary thyroid microcarcinoma: preliminary results[J].Eur Radiol,2017,27(7):2934-2940.DOI:10.1007/s00330-016-4610-1.
[12] Zhang L,Zhou W,Zhan W,et al.Percutaneous laser ablation of unifocal papillary thyroid microcarcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in assessing local therapeutic response[J].World J Surg,2018,42(8):2476-2484.DOI:10.1007/s00268-018-4500-6.
[13] Zhang M,Luo Y,Zhang Y,et al.Efficacy and safety of ultrasound-guided radiofrequency ablation for treating low-risk papillary thyroid microcarcinoma: a prospective study[J].Thyroid,2016,26(11):1581-1587.DOI:10.1089/thy.2015.0471.
[14] Kim JH,Baek JH,Sung JY,et al.Radiofrequency ablation of low-risk small papillary thyroidcarcinoma: preliminary results for patients ineligible for surgery[J].Int J Hyperthermia,2017,33(2):212-219.DOI:10.1080/02656736.2016.1230893.
[15] Jeong SY,Baek JH,Choi YJ,et al.Radiofrequency ablation of primary thyroid carcinoma: efficacy according to the types of thyroid carcinoma[J].Int J Hyperthermia,2018,34(5):611-616.DOI:10.1080/02656736.2018.1427288.
[16] Yue W,Wang S,Yu S,et al.Ultrasound-guided percutaneous microwave ablation of solitary T1N0M0 papillary thyroid microcarcinoma: initial experience[J].Int J Hyperthermia,2014,30(2):150-157.DOI:10.3109/02656736.2014.885590.
[17] Teng D,Sui G,Liu C,et al.Long-term efficacy of ultrasound-guided low power microwave ablation for the treatment of primary papillary thyroid microcarcinoma: a 3-year follow-up study[J].J Cancer Res Clin Oncol,2018,144(4):771-779.DOI:10.1007/s00432-018-2607-7.
[18] Li J,Liu Y,Liu J,et al.Ultrasound-guided percutaneous microwave ablation versus surgery for papillary thyroid microcarcinoma[J].Int J Hyperthermia,2018,34(5):653-659.DOI:10.1080/02656736.2018.1453092.
[19] Teng DK,Li HQ,Sui GQ,et al.Preliminary report of microwave ablation for the primary papillary thyroid microcarcinoma: a large-cohort of 185 patients feasibility study[J].Endocrine,2019,64(1):109-117.DOI:10.1007/s12020-019-01868-2.
[20] 中国抗癌协会甲状腺癌专业委员会(CATO).甲状腺微小乳头状癌诊断与治疗专家共识(2016版)[J].中国肿瘤临床,2016,43(10):405-411.DOI:10.3969/j.issn.1000-8179.2016.10.001.
[21] Ito Y,Miyauchi A,Kihara M,et al.Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J].Thyroid,2014,24(1):27-34.DOI:10.1089/thy.2013.0367.
[22] Kwon H,Oh HS,Kim M,et al.Active surveillance for patients with papillary thyroid microcarcinoma: a single center’s experience in Korea[J].J Clin Endocrinol Metab,2017,102(6):1917-1925.DOI:10.1210/jc.2016-4026.
[23] Yabuta T,Matsuse M,Hirokawa M,et al.TERT promoter mutations were not found in papillary thyroid microcarcinomas that showed disease progression on active surveillance[J].Thyroid,2017,27(9):1206-1207.DOI:10.1089/thy.2016.0645.
[24] Yeh MW,Bauer AJ,Bernet VA,et al.American Thyroid Association statement on preoperative imaging for thyroid cancer surgery[J]. Thyroid,2015,25(1):3-14. DOI:10.1089/thy.2014.0096.
[25] 马奔,王宇,嵇庆海,等.原发性甲状腺癌热消融治疗后再手术2例分析[J].中国实用外科杂志,2016,36(8):875-879.D0I:10.7504/CJPS.ISSN1005-2208.2016.08.15.

相似文献/References:

[1]胡欣,褚晓秋,陈国芳,等.欧洲甲状腺学会/欧洲心血管介入放射学会《甲状腺癌微创治疗的临床实践指南》解读:审时与度势[J].国际内分泌代谢杂志,2023,43(03):278.[doi:10.3760/cma.j.cn121383-20211126-11069]
　Hu Xin,Chu Xiaoqiu,Chen Guofang,et al.[J].International Journal of Endocrinology and Metabolism,2023,43(06):278.[doi:10.3760/cma.j.cn121383-20211126-11069]

备注/Memo

备注/Memo:
通信作者:徐书杭,Email:shuhangxu@163.com; 刘超,Email:liuchao@nfmcn.com
Corresponding author: Xu Shuhang, Email:shuhangxu@163.com; Liu Chao, Email:liuchao@nfmcn.com
基金项目:江苏省“六大人才高峰”项目(2013-WSN-063); 江苏省临床医学科技专项-重点病种的规范化诊疗(BL2013040); 江苏省医院协会医院管理创新研究课题(JSYGY-1-2018-301)
Fund program:The Second Batch of Leading Talent of Traditional Chinese Medicine in Jiangsu Province(SLJ0209); Standardization of Clinical Medical Science and Technology in Jiangsu Province-standardized Diagnosis and Treatment of Key Diseases(BL2013040); Innovation Project on Hospital Management of Jiangsu Provice Hospital Association(JSYGY-1-2018-301)
更新日期/Last Update: 2019-11-20